NewAmsterdam Pharma
Clinical trials sponsored by NewAmsterdam Pharma, explained in plain language.
A biopharmaceutical company developing therapies for cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers sought to test if experimental drug boosts antioxidant absorption. Results expected Sep 2026 (estimated) May already have reported ↗
- New combo aims to crush 'Bad' cholesterol particle that other drugs miss Results expected Nov 2026 (estimated)
-
New combo aims to crush 'Bad' cholesterol particle that other drugs miss
Disease control Recruiting nowThis 16-week study tests whether a daily pill (obicetrapib) plus a twice-monthly shot (evolocumab, sold as Repatha) can lower a fatty particle called lipoprotein(a) that raises heart disease risk. About 69 adults with mildly high cholesterol and elevated Lp(a) will take the pill …
Phase 2 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Healthy volunteers sought to test if experimental drug boosts antioxidant absorption.
Knowledge-focused Recruiting nowThis study tests whether the experimental drug obicetrapib can increase the amount of antioxidants (like lutein and vitamin E) in the blood and eyes of healthy people. One hundred volunteers will take either the drug or a placebo daily for 4 months, with regular blood draws and e…
Phase 2 • Sponsor: NewAmsterdam Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC